Vanderbilt-Ingram Cancer Center

The VICC.ORG Investigator Directory

David Penson, M.D., M.P.H.

Professor of Urologic Surgery
Director, Vanderbilt Center for Surgical Quality and Outcomes Research
VICC Member
Urologic Surgeon/Oncologist

Patient Contact Information:

615-322-2880
Fax: 615-343-9815

Nashville Veterans Affairs Medical Center
1310 24th Ave. South
Nashville , TN 37212-2637
Phone: 615-327-4751
Fax: 615-321-6350

Healthcare Provider Contact Information:

Vanderbilt University Medical Center
2525 West End Avenue, Suite 1200
Nashville, TN 37203-1738
615-343-1529
Fax: 615-875-2655

Profile

Dr. Penson is a board-certified urologic oncologist who focuses on urological malignancies, particularly bladder and prostate cancer.  He is an internationally recognized expert in the care of both of these common cancers and is also a federally funded researcher with a focus on patient-reported outcomes, survivorship and comparative effectiveness in prostate cancer.  He serves as the American Urologic Association National Vice-chair for Healthcare Policy and is the organization's representative to the Commission on Cancer.

Clincial Research Description:

My primary research interest has been in using population-based cohorts and assessing patient-reported outcomes in conditions treated with surgical procedures, specifically prostate cancer. My additional interests include (but are not limited to) cost-effectiveness analyses, exploring disparities in access and quality of care across numerous surgical conditions. I also maintain a focus on improving clinical decision-making.

Publications:

• Penson, DF Editorial Comments. J Urol, 2012.
• Patel, SG, Penson, DF, Pabla, B, Clark, PE, Cookson, MS, Chang, SS, Herrell, SD, Smith, JA, Barocas, DA National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol, 187(3), 816-21, 2012.
• Fowke, JH, Motley, SS, Concepcion, RS, Penson, DF, Barocas, DA Obesity, body composition, and prostate cancer. BMC Cancer, 1223, 2012.
• Penson, DF Re: Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data. J Urol, 187(1), 246, 2012.
• Penson, DF Re: How Well Informed are Women Who Undergo Urodynamic Testing. J Urol, 187(3), 965, 2012.
• Wein, AJ, Penson, DF Re: Retropubic versus transobturator midurethral slings for stress incontinence. J Urol, 187(1), 202-4, 2012.
• Penson, DF Re: Satisfaction profiles in men using intracavernosal injection therapy. J Urol, 187(1), 245-6, 2012.
• Wein, AJ, Penson, DF Re: Transobturator TVT-O versus retropubic TVT: results of a multicenter randomized controlled trial at 24 months follow-up. J Urol, 187(1), 203-4, 2012.
• Penson, DF Re: US physician practices versus Canadians: spending nearly four times as much money interacting with payers. J Urol, 187(2), 648, 2012.
• Penson, DF Re: Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. J Urol, 187(3), 966-7, 2012.
• Wein, AJ, Penson, DF Re: What patients think: patient-reported outcomes of retropubic versus trans-obturator mid-urethral slings for urodynamic stress incontinence--a multi-centre randomised controlled trial. J Urol, 187(1), 203-5, 2012.
• Penson, DF Re: higher fees paid to us physicians drive higher spending for physician services compared to other countries. J Urol, 187(2), 647-8, 2012.
• Penson, DF Re: physician documentation of fluoroscopy time in voiding cystourethrography reports correlates with lower fluoroscopy times: a surrogate marker of patient radiation exposure. J Urol, 187(3), 965-6, 2012.
• Penson, DF Re: today''s ''meaningful use'' standard for medication orders by hospitals may save few lives; later stages may do more. J Urol, 187(2), 646, 2012.
• Makarov, DV, Desai, RA, Yu, JB, Sharma, R, Abraham, N, Albertsen, PC, Penson, DF, Gross, CP The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol, 187(1), 97-102, 2012.
• Fowke, JH, Munro, H, Signorello, LB, Blot, WJ, Penson, DF, , Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med, 26(11), 1305-10, 2011.
• Wessells, H, Penson, DF, Cleary, P, Rutledge, BN, Lachin, JM, McVary, KT, Schade, DS, Sarma, AV, , Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol, 185(5), 1828-34, 2011.
• Reynolds, WS, Dmochowski, RR, Penson, DF Epidemiology of stress urinary incontinence in women. Curr Urol Rep, 12(5), 370-6, 2011.
• Padmanabhan, P, Scarpero, HM, Milam, DF, Dmochowski, RR, Penson, DF Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol, 29(1), 51-7, 2011.
• Birkhahn, M, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG, Cote, RJ Long-term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy. BJU Int, 2011.
• Penson, DF, Munro, HM, Signorello, LB, Blot, WJ, Fowke, JH, , Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J Urol, 186(6), 2316-22, 2011.
• Maripuri, S, Penson, DF, Ikizler, TA, Cavanaugh, KL Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. Am J Nephrol, 34(1), 64-70, 2011.
• Barocas, DA, Motley, S, Cookson, MS, Chang, SS, Penson, DF, Dai, Q, Milne, G, Roberts, LJ, Morrow, J, Concepcion, RS, Smith, JA, Fowke, JH Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. J Urol, 2011.
• Morgan, TM, Keegan, KA, Barocas, DA, Ruhotina, N, Phillips, SE, Chang, SS, Penson, DF, Clark, PE, Smith, JA, Cookson, MS Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol, 186(3), 829-34, 2011.
• Davies, JD, Aghazadeh, MA, Phillips, S, Salem, S, Chang, SS, Clark, PE, Cookson, MS, Davis, R, Herrell, SD, Penson, DF, Smith, JA, Barocas, DA Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol, 186(6), 2221-7, 2011.
• Zeliadt, SB, Penson, DF, Moinpour, CM, Blough, DK, Fedorenko, CR, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU Int, 2011.
• Epplein, M, Zheng, Y, Zheng, W, Chen, Z, Gu, K, Penson, D, Lu, W, Shu, XO Quality of life after breast cancer diagnosis and survival. J Clin Oncol, 29(4), 406-12, 2011.
• Penson, DF Re: Assessment of quality of cancer-related follow-up care from the cancer survivor''s perspective. J Urol, 186(6), 2349, 2011.
• Penson, DF Re: Complementary and Alternative Medicine (CAM) Use in Women With Pelvic Floor Disorders: A Cohort Study. J Urol, 185(4), 1382-3, 2011.
• Penson, DF Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. J Urol, 185(4), 1383-4, 2011.
• Penson, DF Re: Validating the patient safety indicators in the Veterans Health Administration: are they ready for prime time. J Urol, 186(6), 2347-8, 2011.
• Penson, DF Re: can pelvic floor muscle training reverse pelvic organ prolapse and reduce prolapse symptoms? An assessor-blinded, randomized, controlled trial. J Urol, 185(4), 1383, 2011.
• Makarov, DV, Yu, JB, Desai, RA, Penson, DF, Gross, CP The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care, 49(4), 333-9, 2011.
• Morgan, TM, Barocas, DA, Chang, SS, Phillips, SE, Salem, S, Clark, PE, Penson, DF, Smith, JA, Cookson, MS The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urol Oncol, 2011.
• Penson, DF Treatment for postprostatectomy incontinence: is this as good as it gets. JAMA, 305(2), 197-8, 2011.
• McVary, KT, Roehrborn, CG, Avins, AL, Barry, MJ, Bruskewitz, RC, Donnell, RF, Foster, HE, Gonzalez, CM, Kaplan, SA, Penson, DF, Ulchaker, JC, Wei, JT Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J Urol, 185(5), 1793-803, 2011.
• Hadley, J, Yabroff, KR, Barrett, MJ, Penson, DF, Saigal, CS, Potosky, AL Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. J Natl Cancer Inst, 2010.
• Thong, MS, Van De Poll-Franse, L, Hoffman, RM, Albertsen, PC, Hamilton, AS, Stanford, JL, Penson, DF Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU Int, 2010.
• Stimson, CJ, Dmochowski, R, Penson, DF Health care reform 2010: a fresh view on tort reform. J Urol, 184(5), 1840-6, 2010.
• Huang, GJ, Sadetsky, N, Penson, DF Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol, 183(6), 2206-12, 2010.
• Moses, KA, Paciorek, AT, Penson, DF, Carroll, PR, Master, VA Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE. J Clin Oncol, 28(6), 1069-74, 2010.
• Ramsey, SD, Zeliadt, SB, Fedorenko, CR, Blough, DK, Moinpour, CM, Hall, IJ, Smith, JL, Ekwueme, DU, Fairweather, ME, Thompson, IM, Keane, TE, Penson, DF Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World J Urol, 2010.
• Zeliadt, SB, Moinpour, CM, Blough, DK, Penson, DF, Hall, IJ, Smith, JL, Ekwueme, DU, Thompson, IM, Keane, TE, Ramsey, SD Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care, 16(5), e121-30, 2010.
• Barocas, DA, Penson, DF Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU Int, 106(3), 322-8, 2010.
• Makarov, DV, Loeb, S, Landman, AB, Nielsen, ME, Gross, CP, Leslie, DL, Penson, DF, Desai, RA Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol, 183(4), 1504-9, 2010.
• Kantoff, PW, Higano, CS, Shore, ND, Berger, ER, Small, EJ, Penson, DF, Redfern, CH, Ferrari, AC, Dreicer, R, Sims, RB, Xu, Y, Frohlich, MW, Schellhammer, PF, , Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363(5), 411-22, 2010.
• Hamilton, AS, Albertsen, PC, Johnson, TK, Hoffman, R, Morrell, D, Deapen, D, Penson, DF Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int, 2010.
• Ramsey, SD, Zeliadt, SB, Arora, NK, Blough, DK, Penson, DF, Oakley-Girvan, I, Hamilton, AS, Van Den Eeden, SK, Fedorenko, CR, Potosky, AL Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. J Urol, 2010.
• Ramsey, SD, Zeliadt, SB, Arora, NK, Potosky, AL, Blough, DK, Hamilton, AS, Van Den Eeden, SK, Oakley-Girvan, I, Penson, DF Access to information sources and treatment considerations among men with local stage prostate cancer. Urology, 74(3), 509-15, 2009.
• Penson, DF Active surveillance: not your father''s watchful waiting. Oncology (Williston Park), 23(11), 980, 982, 2009.
• Bruins, HM, Huang, GJ, Cai, J, Skinner, DG, Stein, JP, Penson, DF Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol, 182(5), 2182-7, 2009.
• Nichol, MB, Knight, TK, Wu, J, Barron, R, Penson, DF Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol, 181(5), 2214-21; discussion 2221-2, 2009.
• Stein, JP, Penson, DF, Lee, C, Cai, J, Miranda, G, Skinner, DG Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol, 181(5), 2052-8; discussion 2058-9, 2009.
• Zeliadt, SB, Ramsey, SD, Van Den Eeden, SK, Hamilton, AS, Oakley-Girvan, I, Penson, DF, Fairweather, ME, Arora, NK, Potosky, AL Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer. Am J Clin Oncol, 2009.
• Makarov, DV, Penson, DF Prostate cancer: quality of life after radiation and androgen deprivation. Nat Rev Urol, 6(9), 477-8, 2009.
• Penson, DF, Wessells, H, Cleary, P, Rutledge, BN, , Sexual dysfunction and symptom impact in men with long-standing type 1 diabetes in the DCCT/EDIC cohort. J Sex Med, 6(7), 1969-78, 2009.
• Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol, 179(5 Suppl), S40-4, 2008.
• Lloyd, A, Penson, D, Dewilde, S, Kleinman, L Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis, 11(2), 153-9, 2008.
• Etzioni, R, Gulati, R, Falcon, S, Penson, DF Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making, 28(3), 323-31, 2008.
• Huang, GJ, Penson, DF Internet health resources and the cancer patient. Cancer Invest, 26(2), 202-7, 2008.
• Stein, JP, Penson, DF Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int, 102(3), 270-5, 2008.
• Huang, GJ, Hamilton, AS, Lo, M, Stein, JP, Penson, DF Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J Urol, 180(2), 520-4; discussion 524, 2008.
• Penson, DF, Rossignol, M, Sartor, AO, Scardino, PT, Abenhaim, LL Prostate cancer: epidemiology and health-related quality of life. Urology, 72(6 Suppl), S3-11, 2008.
• Etzioni, R, Tsodikov, A, Mariotto, A, Szabo, A, Falcon, S, Wegelin, J, DiTommaso, D, Karnofski, K, Gulati, R, Penson, DF, Feuer, E Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control, 19(2), 175-81, 2008.
• Stein, JP, Penson, DF The invasive T1 bladder tumor: contemporary issues and rationale for radical cystectomy. Curr Urol Rep, 9(3), 179-81, 2008.
• Albertsen, PC, Hanley, JA, Penson, DF, Barrows, G, Fine, J 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol, 177(3), 932-6, 2007.
• Ramsey, SD, Zeliadt, SB, Hall, IJ, Ekwueme, DU, Penson, DF On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol, 177(6), 1992-9, 2007.
• Singer, EA, Penson, DF, Palapattu, GS PSA screening and elderly men. JAMA, 297(9), 949; author reply 949-50, 2007.
• Stein, JP, Penson, DF, Wu, SD, Skinner, DG Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol, 178(3 Pt 1), 756-60, 2007.
• Gonzalez, CM, Penson, D, Kosiak, B, Dupree, J, Clemens, JQ Pay for performance: rationale and potential implications for urology. J Urol, 178(2), 402-8, 2007.
• Zeliadt, SB, Penson, DF Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics, 25(4), 309-27, 2007.
• Graff, JN, Mori, M, Li, H, Garzotto, M, Penson, D, Potosky, AL, Beer, TM Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. J Urol, 177(4), 1307-12, 2007.
• Stein, JP, Penson, DF, Cai, J, Miranda, G, Skinner, EC, Dunn, MA, Groshen, S, Lieskovsky, G, Skinner, DG Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol, 177(3), 876-81; discussion 881-2, 2007.
• Zeliadt, SB, Etzioni, R, Ramsey, SD, Penson, DF, Potosky, AL Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care, 45(2), 154-9, 2007.
• Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF Clinical and psychosocial characteristics of men with erectile dysfunction: baseline data from ExCEED. J Sex Med, 3(6), 1059-67, 2006.
• Yang, CC, Porter, MP, Penson, DF Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other. BJU Int, 98(1), 105-9; discussion 109, 2006.
• Latini, DM, Penson, DF, Wallace, KL, Lubeck, DP, Lue, TF Longitudinal differences in psychological outcomes for men with erectile dysfunction: results from ExCEED. J Sex Med, 3(6), 1068-76, 2006.
• Black, PC, Penson, DF Prostate cancer on the Internet--information or misinformation. J Urol, 175(5), 1836-42; discussion 1842, 2006.
• Sanderson, KM, Penson, DF, Cai, J, Groshen, S, Stein, JP, Lieskovsky, G, Skinner, DG Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol, 176(5), 2025-31; discussion 2031-2, 2006.
• Zeliadt, SB, Potosky, AL, Penson, DF, Etzioni, R Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys, 66(2), 395-402, 2006.
• Penson, D, Moul, J, Gandhi, S, Newling, D Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. Urology, 68(1), 80-4, 2006.
• Penson, DF, McLerran, D, Feng, Z, Li, L, Albertsen, PC, Gilliland, FD, Hamilton, A, Hoffman, RM, Stephenson, RA, Potosky, AL, Stanford, JL 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol, 173(5), 1701-5, 2005.
• Porter, MP, Penson, DF Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol, 173(4), 1318-22, 2005.
• Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M, Penson, D Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide. Urology, 66(4), 835-9, 2005.
• Zeliadt, SB, Etzioni, RD, Penson, DF, Thompson, IM, Ramsey, SD Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med, 118(8), 850-7, 2005.
• Albertsen, PC, Hanley, JA, Barrows, GH, Penson, DF, Kowalczyk, PD, Sanders, MM, Fine, J Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst, 97(17), 1248-53, 2005.
• Penson, DF, Ramsey, S, Veenstra, D, Clarke, L, Gandhi, S, Hirsch, M The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. J Urol, 174(2), 547-52; discussion 552, 2005.
• Inoue, LY, Etzioni, R, Slate, EH, Morrell, C, Penson, DF Combining longitudinal studies of PSA. Biostatistics, 5(3), 483-500, 2004.
• Rosenfeld, B, Roth, AJ, Gandhi, S, Penson, D Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psychooncology, 13(11), 800-7, 2004.
• Potosky, AL, Davis, WW, Hoffman, RM, Stanford, JL, Stephenson, RA, Penson, DF, Harlan, LC Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst, 96(18), 1358-67, 2004.
• Zeliadt, SB, Potosky, AL, Etzioni, R, Ramsey, SD, Penson, DF Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology, 64(6), 1171-6, 2004.
• Johnson, TK, Gilliland, FD, Hoffman, RM, Deapen, D, Penson, DF, Stanford, JL, Albertsen, PC, Hamilton, AS Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer. J Clin Oncol, 22(20), 4193-201, 2004.
• Neuhouser, ML, Kristal, AR, Penson, DF Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature. Urology, 64(2), 201-11, 2004.
• Penson, DF, Moul, JW, Evans, CP, Doyle, JJ, Gandhi, S, Lamerato, L The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol, 171(6 Pt 1), 2250-4, 2004.
• Albertsen, PC, Hanley, JA, Penson, DF, Fine, J Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol, 171(6 Pt 1), 2221-5, 2004.
• Plaskon, LA, Penson, DF, Vaughan, TL, Stanford, JL Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev, 12(7), 604-9, 2003.
• Penson, DF, Latini, DM, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF, , Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care, 26(4), 1093-9, 2003.
• Penson, DF, Feng, Z, Kuniyuki, A, McClerran, D, Albertsen, PC, Deapen, D, Gilliland, F, Hoffman, R, Stephenson, RA, Potosky, AL, Stanford, JL General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol, 21(6), 1147-54, 2003.
• Penson, DF, Latini, DM, Lubeck, DP, Wallace, K, Henning, JM, Lue, T Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the ExCEED data base. J Urol, 169(4), 1458-61, 2003.
• Latini, DM, Penson, DF, Lubeck, DP, Wallace, KL, Henning, JM, Lue, TF Longitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction study. J Urol, 169(4), 1437-42, 2003.
• Zeliadt, SB, Penson, DF, Albertsen, PC, Concato, J, Etzioni, RD Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 98(3), 496-503, 2003.
• Penson, DF, Grossfeld, GD, Li, YP, Henning, JM, Lubeck, DP, Carroll, PR How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. J Urol, 167(4), 1653-7; discussion 1657-8, 2002.
• Etzioni, R, Penson, DF, Legler, JM, di Tommaso, D, Boer, R, Gann, PH, Feuer, EJ Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst, 94(13), 981-90, 2002.
• Latini, DM, Penson, DF, Colwell, HH, Lubeck, DP, Mehta, SS, Henning, JM, Lue, TF Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol, 168(5), 2086-91, 2002.
• Penson, DF, Paltiel, AD, Krumholz, HM, Palter, S The cost-effectiveness of treatment for varicocele related infertility. J Urol, 168(6), 2490-4, 2002.
• Penson, DF, Albertsen, PC, Nelson, PS, Barry, M, Stanford, JL Determining cause of death in prostate cancer: are death certificates valid. J Natl Cancer Inst, 93(23), 1822-3, 2001.
• Penson, DF, Schonfeld, WH, Flanders, SC, Henke, CJ, Warolin, KL, Carroll, PR, Litwin, MS Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CAPSURE database. Urology, 57(3), 499-503, 2001.
• Penson, DF, Stoddard, ML, Pasta, DJ, Lubeck, DP, Flanders, SC, Litwin, MS The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. J Clin Epidemiol, 54(4), 350-8, 2001.
• Corman, JM, Penson, DF, Hur, K, Khuri, SF, Daley, J, Henderson, W, Krieger, JN Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. BJU Int, 86(7), 782-9, 2000.
• Taneja, SS, Penson, DF, Epelbaum, A, Handler, T, Lepor, H Does site specific labeling of sextant biopsy cores predict the site of extracapsular extension in radical prostatectomy surgical specimen. J Urol, 162(4), 1352-7; discussion 1357-8, 1999.
• Penson, DF, Litwin, MS, Lubeck, DP, Flanders, S, Pasta, DJ, Carroll, PR Transitions in health-related quality of life during the first nine months after diagnosis with prostate cancer. Prostate Cancer Prostatic Dis, 1(3), 134-143, 1998.
• Penson, DF, Ng, C, Rajfer, J, Gonzalez-Cadavid, NF Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology, 138(9), 3925-32, 1997.
• Penson, DF, Lugg, JA, Coyne, C, Sadeghi, F, Freedman, AL, Gonzalez-Cadavid, NF, Rajfer, J Effect of cryptorchidism on testicular histology in a naturally cryptorchid animal model. J Urol, 158(5), 1978-82, 1997.
• Lugg, JA, Penson, DF, Sadeghi, F, Petrie, B, Freedman, AL, Gonzalez-Cadavid, NF, Hikim, AS, Rajfer, J Prevention of seminiferous tubular atrophy in a naturally cryptorchid rat model by early surgical intervention. J Androl, 17(6), 726-32, 1996.

Education

• M.P.H. - Yale University, 2000
• M.D. - Boston University, 1991
• Residency - UCLA Health System, 1997
• Fellowship - UCLA Health System, 1993